Enterprise Europe Network
Register
Register
Register

Pepkon

Therapeutics & Diagnostics

www.pepkon.frParis, France
3 profile visits

About

Pepkon is a French biotechnology company developing first-in-class peptides to treat refractory and incurable cancers. Leveraging ten years of academic research, Pepkon designs CD47-agonist peptides derived from thrombospondin-1 (TSP-1).

Backed by patents filed in 2025, Pepkon is currently conducting pharmacological and toxicity studies, and will start IND-enabling studies in a few months on its lead candidate.

MEDICINE

Cytology, Cancerology, OncologyPharmaceutical Products / Drugs

THERAPEUTIC AREA

HematologyImmunologyOncologyPediatrics/NeonatologyPharmacology/ToxicologyRare Disease

LIFE SCIENCE

Therapy and physical medicine

Representatives

Project manager

Pepkon

CEO

Pepkon